Stem Cells, Mitochondrial Disease, and the United Kingdom’s Ethical Dilemma

As the Vatican prepares to host the Second International Conference on Regenerative Medicine, stem cells have been pushed once again into the international spotlight. In the medical community, tangible progress in the last six months has sparked much conversation of the next steps in bringing therapies to the public.

Read more »

OneMedRadio: Intellicell BioSciences CEO Talks Stromal Vascular Cells

Intellicell BioSciences (OTC: SVFC) has pioneered a unique method of acquiring stromal vascular fraction cells derived from the blood vessels in the adult adipose tissue. The company’s proprietary protocol can separate adult autologous VFC cells from the adipose tissue without the use of enzymes.

Read more »

BREAKING: Pluristem Announces Pricing of Public Offering

Pluristem Therapeutics Inc. announced that it has priced a firm commitment underwritten public offering of 8,000,000 units, with each unit consisting of one share of the company’s common stock and one warrant to purchase 0.35 of a share of the company’s common stock, at a purchase price of $4.00 per unit for an aggregate gross offering amount of $32 million. The offering is expected to close on or about September 19, 2012, subject to customary closing conditions.

Read more »

The Briefing Room, September 5: Today in Microcap Biotech Stocks

OneMedPlace introduces a new series, “The Briefing Room”, capturing the most important developments in microcap life sciences indexes. This week, we focus on three interesting developments in oncology, and a special bonus!

Read more »

ThermoGenesis Sees Explosive Growth Opportunities in Stem Cells

Mel Engle, CEO of ThermoGenesis [NASDAQ: KOOL] recently discussed with OneMedRadio, the company’s stem cell products and FDA approval that may have groundbreaking implications for the stem cell market.

Read more »

Cytori Therepeutics Featured in Wired Magazine

Wired magazine recently published a feature on Cytori Therapeutics, a regenerative medicine company based in San Diego that is using stem and regenerative stem cells derived from fat (adipose) tissue to repair breasts disfigured by mastectomies and lumpectomies.

Read more »

Cardiogenesis Breaks Ground on Heart-Pumping New Research

Cardiogenesis, the clinical and market leader in transmyocardial revascularization (TMR), revealed this week that it has enrolled its first two patients for its feasibility study involving the cutting-edge PHOENIX System.

Read more »

PAD Awareness Month Brings Often-Overlooked Cardiovascular Disease to the Forefront

While most people are familiar with the big-name heart problems such as cardiac arrest and congestive heart failure, PAD is often overlooked.

Read more »

Cytori’s Cardiac Celution: Encouraging Interim Data

In the area of heart disease, Cytori Therapeutics (NASDAQ: CYTX) is sponsoring two European clinical trials that evaluate the use of adipose-derived stem and regenerative cells (ADRCs) to treat acute myocardial infarction and chronic myocardial ischemia.

Read more »